Use of atypical antipsychotics for treatment-resistant major depressive disorder.
about
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Treatment-resistant depression in primary care across CanadaAugmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative studyThe combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.
P2860
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@en
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@nl
type
label
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@en
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@nl
prefLabel
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@en
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@nl
P1476
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
@en
P2093
George I Papakostas
Richard C Shelton
P2888
P304
P356
10.1007/S11920-008-0077-3
P407
P577
2008-12-01T00:00:00Z